Abstract:Diabetes mellitus (DM) is a serious chronic disease characterized by abnormally high blood glucose (Glu) levels, which can cause organ malfunction and metabolic disturbances. However, traditional biomarkers like Glu face limitations due to intraday fluctuations and inability to detect early stages of DM. To tackle these challenges, this study has introduced a colorimetric-fluorescence dual-mode biosensor utilizing α-glucosidase (α-GAA), which enables early diabetes screening without being influenced by physiological fluctuations in blood glucose levels. Specifically, chitosan-modified copper nanoclusters (Cu NC@CS-Ce3+: AP-CuCC) with exceptional peroxidase (POD) activity and Ce3+-induced aggregate-induced luminescence (AIE) properties have been synthesized. The targeted hydrolysis of the α-GAA substrate, 4-nitrophenyl-α-D-glucopyranoside (pNGP), results in the formation of p-nitrophenol (p-NP) and Glu. While p-NP statically quenches an increase in AP-CuCC fluorescence signal, Glu facilitates the production of H2O2 by glucose oxidase during AP-CuCC POD enzyme reactions, triggering colorimetric changes in the reaction. The detection limits for colorimetric and fluorescence measurements were determined to be 0.03 U/L and 0.02 U/L, respectively. By integrating fluorescence analysis, this method cleverly mitigates the confusing effects of normal blood Glu levels on colorimetric outcomes, allowing for the consideration of abnormal Glu levels as a supplementary diagnostic tool. Compared to relying solely on colorimetry, this dual-mode approach reduces false positive rates by 50% and false negative rates by 25%. Leveraging the sensor's colorimetric and fluorescent capabilities provides a versatile platform for precise and reliable evaluation of aberrant expression markers across various clinical settings.

Personal Glucose Sensor for Point-Of-Care Early Cancer Diagnosis

Sensitive glucometer-based microfluidic immune-sensing platform via DNA signal amplification coupled with enzymatic reaction

Point-of-care Testing of Protein Biomarkers by Integrating a Personal Glucose Meter with a Concatenated DNA Amplifier

Cascaded nanozyme-based high-throughput microfluidic device integrating with glucometer and smartphone for point-of-care pheochromocytoma diagnosis

Sucrose‐Powered Liposome Nanosensors for Urinary Glucometer‐Based Monitoring of Cancer

Tyramine-Invertase Bioconjugate-Amplified Personal Glucose Meter Signaling for Ultrasensitive Immunoassay

Dual Signal Amplification of Glucose Oxidase-Functionalized Nanocomposites As a Trace Label for Ultrasensitive Simultaneous Multiplexed Electrochemical Detection of Tumor Markers

Quantitative and Selective DNA Detection with Portable Personal Glucose Meter Using Loop-Based DNA Competitive Hybridization Strategy

An Exploration of Nucleic Acid Liquid Biopsy Using a Glucose Meter.

Integration of Solution-Based Assays Onto Lateral Flow Device for One-Step Quantitative Point-of-Care Diagnostics Using Personal Glucose Meter

Ultrasensitive and multiplexed Gastric cancer biomarkers detection with an integrated electrochemical immunosensing platform

Using a Personal Glucose Meter and Alkaline Phosphatase for Point-of-Care Quantification of Galactose-1-Phosphate Uridyltransferase in Clinical Galactosemia Diagnosis.

Glucose detection: In-situ colorimetric analysis with double-layer hydrogel microneedle patch based on polyvinyl alcohol and carboxymethyl chitosan

AIE multifunctional probe empowering colorimetric-fluorescence dual-mode biosensor for early diabetic screening

A Gel-Based Separation-Free Point-of-Care Device for Whole Blood Glucose Detection

Wireless Non-Enzymatic Glucose Sensing System with Pt-Ni Nanocomposite and Silica Nanoporous Membrane Modified Electrodes for Different Disease Monitoring

Disposable immunosensor array for ultrasensitive detection of tumor markers using glucose oxidase-functionalized silica nanosphere tags.

Point-of-care Monitoring of Intracellular Glutathione and Serum Triglyceride Levels Using a Versatile Personal Glucose Meter

Direct glucose sensing in the physiological range through plasmonic nanoparticle formation

Recent Advances of Using Personal Glucose Meter As a Biosensor Readout for Non-glucose Targets

Using a Glucose Meter to Quantitatively Detect Disease Biomarkers Through a Universal Nanozyme Integrated Lateral Fluidic Sensing Platform.